Hardman Johnston Global Advisors’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-273,462
| Closed | -$50.3M | – | 74 |
|
|
2025
Q4 | $50.3M | Sell |
273,462
-7,329
| -3% | -$1.29M | 2.4% | 12 |
|
|
2025
Q3 | $43.1M | Buy |
280,791
+4,462
| +2% | +$675K | 2.12% | 14 |
|
|
2025
Q2 | $38.6M | Sell |
276,329
-4,614
| -2% | -$647K | 1.71% | 21 |
|
|
2025
Q1 | $41.3M | Buy |
280,943
+19,361
| +7% | +$2.8M | 1.97% | 16 |
|
|
2024
Q4 | $34.3M | Sell |
261,582
-17,662
| -6% | -$2.47M | 1.41% | 24 |
|
|
2024
Q3 | $43.5M | Sell |
279,244
-4,901
| -2% | -$791K | 1.71% | 19 |
|
|
2024
Q2 | $44.3M | Sell |
284,145
-8,479
| -3% | -$1.28M | 1.71% | 20 |
|
|
2024
Q1 | $39.7M | Sell |
292,624
-19,862
| -6% | -$2.63M | 1.37% | 26 |
|
|
2023
Q4 | $42.1M | Sell |
312,486
-14,328
| -4% | -$1.86M | 1.35% | 24 |
|
|
2023
Q3 | $44.3M | Sell |
326,814
-8,494
| -3% | -$1.16M | 1.49% | 22 |
|
|
2023
Q2 | $48M | Sell |
335,308
-7,073
| -2% | -$1.04M | 1.56% | 21 |
|
|
2023
Q1 | $47.5M | Sell |
342,381
-5,442
| -2% | -$732K | 1.55% | 20 |
|
|
2022
Q4 | $47.2M | Sell |
347,823
-43,165
| -11% | -$5.41M | 1.85% | 15 |
|
|
2022
Q3 | $42.9M | Sell |
390,988
-5,713
| -1% | -$725K | 1.93% | 18 |
|
|
2022
Q2 | $52.4M | Sell |
396,701
-124,244
| -24% | -$16.3M | 2.23% | 16 |
|
|
2022
Q1 | $69.1M | Sell |
520,945
-9,610
| -2% | -$1.15M | 2.22% | 13 |
|
|
2021
Q4 | $61.8M | Sell |
530,555
-31,890
| -6% | -$3.75M | 1.67% | 18 |
|
|
2021
Q3 | $67.6M | Buy |
562,445
+3,780
| +0.7% | +$440K | 1.82% | 16 |
|
|
2021
Q2 | $66.9M | Buy |
558,665
+169,831
| +44% | +$18.6M | 1.62% | 16 |
|
|
2021
Q1 | $38.7M | Sell |
388,834
-83,105
| -18% | -$8.35M | 1.1% | 21 |
|
|
2020
Q4 | $47.2M | Sell |
471,939
-25
| -0% | -$2.65K | 1.37% | 15 |
|
|
2020
Q3 | $51.7M | Buy |
471,964
+16,818
| +4% | +$1.87M | 1.94% | 13 |
|
|
2020
Q2 | $48.1M | Sell |
455,146
-79,418
| -15% | -$8.2M | 2.12% | 12 |
|
|
2020
Q1 | $47.7M | Sell |
534,564
-26,095
| -5% | -$2.46M | 2.78% | 9 |
|
|
2019
Q4 | $55.9M | Sell |
560,659
-525
| -0.1% | -$49.4K | 2.26% | 11 |
|
|
2019
Q3 | $50M | Buy |
561,184
+760
| +0.1% | +$65.9K | 2.29% | 13 |
|
|
2019
Q2 | $46.3M | Sell |
560,424
-5,615
| -1% | -$440K | 2.05% | 13 |
|
|
2019
Q1 | $45.8M | Buy |
566,039
+3,406
| +0.6% | +$268K | 2.01% | 13 |
|
|
2018
Q4 | $42.7M | Sell |
562,633
-106,007
| -16% | -$8.28M | 2.21% | 13 |
|
|
2018
Q3 | $52.9M | Buy |
668,640
+53,160
| +9% | +$4.02M | 2.28% | 12 |
|
|
2018
Q2 | $43.2M | Sell |
615,480
-5,961
| -1% | -$429K | 1.83% | 13 |
|
|
2018
Q1 | $43.5M | Buy |
621,441
+115,313
| +23% | +$7.99M | 1.85% | 14 |
|
|
2017
Q4 | $35.1M | Buy |
+506,128
| New | +$34.1M | 1.49% | 20 |
|
Other funds holding AZN
IA
VCM
VAM
Hardman Johnston Global Advisors's AZN Position: Q1 2026 in Review
Hardman Johnston Global Advisors sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 273,462 shares — an estimated $50.3M sold.
Hardman Johnston Global Advisors first reported a position in AZN in Q4 2017 and held it in 33 quarters. The position peaked at $69.1M in Q1 2022. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Hardman Johnston Global Advisors reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
- Hardman Johnston Global Advisors sold 273,462 AstraZeneca shares in Q1 2026, an estimated $50.3M.
- Hardman Johnston Global Advisors first reported a position in AstraZeneca in Q4 2017 and held it in 33 quarters.
- Hardman Johnston Global Advisors's AstraZeneca position peaked at $69.1M in Q1 2022.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Hardman Johnston Global Advisors's 13F filing for Q1 2026, filed 13 May 2026.